Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

Johnson & Johnson is normally a good buy for its dividend and the stability it offers. Over the past five years, however, the stock has risen by around just 3%. This is not the type of investment ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

The U.S. Food and Drug Administration has approved a nasal spray that is known to help treat depression.

The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

"Treatment-resistant depression can be very complicated ... neuroscience leader with the drug’s manufacturer, Johnson & Johnson, said in a news release. “For too long, health care providers ...

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray ... treatment is poised to change the landscape of depression management, particularly for those grappling ...